[Pharmacological aspects of secondary prevention post-MI].
The pharmacological evaluation of medications used in secondary prevention of myocardial infarction offers interesting insights that facilitate the individualization of therapy. One example is the strong evidence of a reduced patient benefit with comedication of ACE inhibitors and acetylsalicylic acid after myocardial infarction. Over the past years, the effects of n-3-polyunsaturated-fatty acids after myocardial infarction have been investigated intensely. They act via several physiological mechanisms that are of potential benefit in reducing cardiovascular mortality. While epidemiological and study data suggest antiarrhythmic properties as the main reason for reduced mortality, recent papers also point to a intensification of plaque stability.
Schrör
K
K
Institut für Pharmakologie und klinische Pharmakologie, Heinrich-Heine-Universität Düsseldorf, Moorenstrasse 5, 40225 Düsseldorf, Germany.
D000359:Aftercare; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D001241:Aspirin / Q000008:administration & dosage* / Q000009:adverse effects; D002317:Cardiovascular Agents / Q000008:administration & dosage / Q000009:adverse effects; D002986:Clinical Trials as Topic; D003324:Coronary Artery Disease / Q000188:drug therapy / Q000401:mortality; D015525:Fatty Acids, Omega-3 / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000401:mortality; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D055502:Secondary Prevention; D015996:Survival Rate; D016896:Treatment Outcome
D000806:Angiotensin-Converting Enzyme Inhibitors; D002317:Cardiovascular Agents; D015525:Fatty Acids, Omega-3; D010975:Platelet Aggregation Inhibitors; D001241:Aspirin